Lantheus

Company Snapshot

Founded: 1956
Entity Type: Public
Employees: 808
Region: U.S.
Revenue: $1,533.9 Millions
Revenue Year: 2024
Headquarter: Massachusetts, U.S.
Key Geographics: North America
Corporate Address: 201 Burlington Road, South Building Bedford, Massachusetts 0173 U.S. Tel. +1-978-671-800 www.lantheus.com

Company Overview

Lantheus Holdings, Inc., is a leading radiopharmaceutical company. It classifies its products into three categories: Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. The Radiopharmaceutical Oncology segment includes diagnostics and therapeutics, with a focus on prostate cancer. The Precision Diagnostic segment includes diagnostics with a focus on cardiology. The Strategic Partnerships focus on enabling personalized medicine using biomarkers, digital solutions and pharma solutions platforms.

Lantheus produces and markets its products throughout the U.S., selling primarily to hospitals, independent diagnostic testing facilities, and radio pharmacies. Lantheus sells its products outside the U.S. through direct distribution in Canada and third-party distribution relationships in Europe, Canada, Australia, Asia-Pacific, Central America, and South America.

Financial Highlights (FY 2024)

Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***

This information is available for BCC Research members only.

Lantheus In Reports

Radiopharmaceuticals: Technologies and Global Markets

BCC Research Report: Dive into radiopharmaceuticals market report includes global revenue ($ Million) for base year data of 2023 and estimated data for the forecast period 2024 through 2029.

Theranostics: Global Markets

BCC Research Market Analyst says global market for theranostics was valued at $3.7 billion in 2023 & expected to grow from $4.3 billion in 2024 to $12.7 billion by the end of 2029.

Radiotherapy, Radiopharmaceuticals and Nuclear Medicine: Global Markets

BCC Research Market Analyst says global market for global market for radiation therapy products and radiopharmaceuticals is expected to grow from $17.5 billion in 2024 and is projected to reach $31.3 billion by the end...

Company's Business Segments

  • Radiopharmaceutical Oncology : This segment includes PYLARIFY, Other radiopharmaceutical oncology.
  • Precision Diagnostics : This segment includes DEFINITY, TechneLite, Other precision diagnostics.

Applications/End User Industries

  • Healthcare
  • Pharmaceuticals
  • Radiopharmaceuticals
  • Oncology
  • Diagnostics
  • Precision Diagnostics
AI Sentiment